
Clinical Trials - April 28, 2015
Trial Starts for PPMS Drug
Teva Pharmaceutical Industries Ltd. and Active Biotech enrolled the first patient in their study A RandomizedPlacebo-controlled Trial Evaluating Laquinimod in primary progressive multiple sclerosis (PPMS), Gauging Gradations In MRI and Clinical Outcomes (ARPEGGIO), a Phase II study to evaluate laquinimod. This is an investigational, oral, immune modulator, for PPMS, which currently has no approved treatments. PPMS affects approximately 15 percent of all MS patients […]

Clinical Trials - August 15, 2014
Active Biotech’s partner Teva starts laquinimod clinical trial
Active Biotech has announced that its partner Teva Pharmaceutical Industries Ltd. will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington’s disease. Teva started a global research collaboration in the summer of 2013 to develop laquinimod as a treatment for Huntington’s disease. Earlier this year, […]